Low bisphosphonate use seen in men on ADT

December 8, 2014

Use of bisphosphonates in men on androgen deprivation therapy (ADT) for prostate cancer remains low despite the fact that the practice is recommended in several guidelines, Canadian researchers say.

Use of bisphosphonates in men on androgen deprivation therapy (ADT) for prostate cancer remains low despite the fact that the practice is recommended in several guidelines, Canadian researchers say.

Bisphosphonate prescriptions are low even in men with high risk of subsequent fractures, the authors wrote in a research letter in JAMA (2014; 312:2285-6).

RELATED: Prostate Ca assays show economic, clinical benefits

Canadian guidelines recommended bisphosphonate use in men with osteoporosis or fragility fracture as early as 2002 and in men on ADT in 2006, according to a press release from JAMA. Bisphosphonate prescribing patterns are relatively unknown and may have changed over time because of increasing awareness of bone effects of ADT and evidence of bisphosphonate efficacy, according to background information in the research letter.

Researchers led by first author Husayn Gulamhusein, BHSc, of the University Health Network, Toronto examined rates of bisphosphonate prescriptions in men initiating ADT in Ontario between 1995 and 2012. The study group included men 66 years of age or older starting ADT for prostate cancer who had undergone orchiectomy or received at least 6 months of continuous medical ADT and survived at least 1 year after ADT initiation.

Bisphosphonate prescription over time was examined for three groups: all nonusers of bisphosphonates, those with prior osteoporosis, and those with prior fragility fracture. A total of 35,487 men with prostate cancer who began ADT during the study period were identified.

Among the authors’ findings:

  • Bisphosphonate claims among all nonusers increased from 0.35 per 100 persons in 1995-1997 to 3.40 per 100 persons in 2010-2012.

  • Even among those with prior osteoporosis or fragility fracture, rates remained low.

  • Among all three groups, peak bisphosphonate claims occurred in 2007-2009, with a high of 11.89 per 100 persons in those with prior osteoporosis.

As the most widely used class of prescription drugs for osteoporosis, the authors wrote that these findings suggest “limited awareness among clinicians regarding optimal bone health management.”

Next: Decrease in use in high-risk patients "concerning"

More recent Urology Times articles

European agencies follow FDA lead on T, CV risk

Attention thought leaders: How is new-onset flank pain evaluated?

Companies acquire rights to low T, IC drugs
 

 

The researchers speculate that the decrease in bisphosphonate prescriptions after 2009 may be partly due to recent negative media regarding the association of bisphosphonates with rare osteonecrosis of the jaw and atypical femoral fractures. “This is appropriate for groups at low risk for fractures, but the decrease in use for high-risk patients is concerning,” they wrote.

“Although the optimal rate of bisphosphonate use in men on ADT is unknown, it is reasonable that most men with prior osteoporosis or fracture should be taking a bisphosphonate or other effective bone medication.”

To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.